|
 |
| home > epc > Summer 2003 |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of EPC |
 |
| |
|
|
In her first Editor's Letter, Julia Lloyd-Parks reviews the articles in this Summer 2003 issue
|
|
|
|
|
| Dr Grant Coren, Pharmaceutical Practice Leader at Astralis Group Plc, examines Uneasy Alliances - Managing the Relationships in Alliances and Joint Ventures |
|
|
| The majority of drug patents will expire before 2010 and the race is on to fill the emptying pipeline for new products. Guy Malchi, Director of the Life Science Division at Tefen UK Operations Management Consulting, takes us From Pipe Dreams to Reality |
|
|
| A worldwide survey in 2002 found that only 53 per cent of companies have a business continuity plan. Chris Tait, Life Science Account Manager at Chubb Insurance Company of Europe, asks why Life Science Companies Don't Plan to Fail, But Often Fail to Plan |
|
|
| Ben Rapinoja and Kristiina Laiho, Attorneys at law Borenius & Kemppinen Ltd, outline Legal Due Diligence and Biotech Transactions - Practical Aspects |
|
|
|
| Julia Lloyd-Parks, Editor of EPC and Senior Consultant at Technomark Consulting Services, conducts An Interview with John Kolthammer, Chief Executive Officer of the Institute of Clinical Research |
|
|
| Competitive pressures are forcing pharmaceutical companies to carefully examine the process of drug development. Dr Paul Bleicher, MD, PhD, Founder and Chairman at Phase Forward, Inc looks at ways of achieving shareholder value while controlling costs in, Managing the Information Supply Chain in Clinical Trials |
|
|
| Audrey Bottomley, David Myers and Chris Willoughby of the Reproductive Studies Group at Huntingdon Life Sciences, discuss the potential benefits of using young animals in preclinical studies, in Preclinical Juvenile Toxicity Studies: Will it be Safe for Children? |
|
|
| The chemical pathology or clinical chemistry laboratory provides biochemical information for the management of patients and/or trial subjects. Johann Terblanchй, Senior Director and Head, Clinical Division at Farmovs-Parexel, gives us a detailed examination of Abnormal Laboratory Findings in Healthy Subjects: Biochemical Tests in Clinical Research |
|
|
|
|
| New FDA draft guidance recommends the use of risk assessment techniques for 21 CFR Part 11; however it does not offer any help on how to conduct risk assessment. Sam Brooks, Principal Compliance Consultant at ABB Switzerland, is at hand with 21 CFR Part 11 - GAMP Risk Assessment Methodology for Delivering Compliance Measures |
|
|
| Wolfgang Winter, Senior Product Manager Networked Data Systems at Agilent Technologies GmbH, revisits Electronic Records and Electronic Signatures in The Impact of the New 21 CFR Part 11 Guidance on Data Systems and Networks in GxP Environments |
|
|
| In the second instalment of her article, Dr Manja Epping, Lawyer at Ashurst Morris Crisp, looks at Data Exclusivity Under Review - Striking the Balance Between Originator and Generic Medicines |
|
|
|
| Christopher Searcy, Vice President of Corporate Development at Nektar Therapeutics, explores Drug Delivery: An Evolving Concept |
|
|
| The importance of medical delivery devices with features that enable the non-invasive delivery of drugs is obvious. In The Application of Regimen Assurance and Assistance Devices for Future Inhaleable Pain Management Therapies, Chris Halling, Marketing Manager at Bespak considers the potential |
|
|
| Peter Fyhr, R&D Director, and Ken Downie, Director of Business Development, at Amarin Development AB, explore advances in Oral Drug Delivery Technology |
|
|
|
|
| Only a few companies have implemented electronic data capture and electronic study management services as their standard clinical trial technology. Dr Max Horneck, Chief Technical Officer at clinIT AG, outlines Introducing e-Clinical Trial Systems Toda |
|
|
| The Future of Electronic Data Capture in Clinical Trials is predicted by Tony Dean, Director of Sales and Marketing at Datatrial Ltd |
|
|
| Agostino Renna, Director of Life Sciences, Americas, and Matthias Maaz, Director of Life Sciences, Europe, at Johnson Controls, Inc., examine Validation Requirements for Building Management Systems in Pharmaceutical and Biomedical Manufacturing Facilities |
|
|
|
| In The Technology Conundrum: New and Old Technologies in Drug Discovery, Dr Roy Massingham BSc PhD, Director of Research Europe at UCB-Pharma, looks more closely at drug discovery and the lessons learned over the last 25 years |
|
|
| Henri Snijder, European Business Development Manager LC/MS Small Molecules at Applied Biosystems, describes Advances in LC/MS/MS for Drug Metabolite Characterisation e-DATA |
|
|
|
| Evolving standards and technologies make e-logistics in temperature-controlled, on-time shipment delivery increasingly challenging. In E-Logistics in Cold Chain Management, Alastair Black, Project Director at Quintiles Clinical Supplies Europe, assesses the facts |
|
|
| Katrina Bray, Marketing Manager at Laminar Medica Limited, tells us why It's in the Bag: Shipping Infectious Substances and Diagnostic Specimens by Air Made Easy |
|
|
|
|
| Bioterrorism: Preparing For the Worst. An overview from Terri Rebmann, Infectious Disease Specialist for the Center for the Study of Bioterrorism and Emerging Infections (CSB&EI) at Saint Louis University, School of Public Health |
|
|
| Nicolas Higgins, Chief Business Officer at Acambis, takes the threat of smallpox as an example, in Testing for Biosecurity Vaccines |
|
|
|
| Julia Lloyd-Parks, Editor of EPC, and Dr Graham Hughes at Technomark Consulting Services Limited, report direct from DIA Euromeeting Rome, 3rd-10th March 2003 |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
PFIZER PRESENTS OVERALL SURVIVAL DATA FOR SUTENT™ VERSUS INTERFERON-ALFA
Chicago, 31 May 2008- Results from a landmark study have shown that sunitinib (SUTENT™)
has demonstrated overall survival greater than two years in patients with
metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer.
This is the first time overall survival data representing more than two years
has been achieved in the first line setting of mRCC, which is clinically
meaningful and reflective of major advances in the treatment of kidney
cancer.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
